WARNING LETTER
ZIIP, Inc.
MARCS-CMS 725870 —
May 22, 2026
Delivery Method:
VIA Electronic Mail
Product:
Medical Devices
Recipient:
Recipient Name
Mr. David Mason
Recipient Title
General Manager
ZIIP, Inc.
2495 Estand Way
Pleasant Hill
,
CA
94523-3911
United States
(b)(6), (b)(7)(C)
Issuing Office:
Center for Devices and Radiological Health
United States
WARNING LETTER
CMS # 725870
May 22, 2026
Dear Mr. Mason:
During an inspection of your firm located in Pleasant Hill, CA from January 5, 2026, through January 12, 2026, investigators from the United States Food and Drug Administration (FDA) determined that your firm manufactures the ZIIP HALO device. Your website and other materials refer to both the HALO and the HALO 2.0. In addition, we have also reviewed your website at https://ziipbeauty.com and have determined that your firm markets the ZIIP DOT and the ZIIP Gels as well. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.
Quality System Regulation Violations
This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21,
Code of Federal Regulations
(CFR), Part 820.
We received responses from Marie Touriel, Quality Manager, dated February 3, 2026 and May 15, 2026, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address the responses below, in relation to each of the noted violations. These violations include, but are not limited to, the following:
1. Failure to ensure that design verification confirmed that design outputs meet design input requirements, as required by 21 CFR 820.30(f). Specifically,
a. Your firm's design control procedures, SOP-13, versions 2.0 and C, and SOP-14, Design Verification & Validation, established requirements for design verification from 03/21/2019 to 05/26/2025. Your firm documents design verification in design verification reports. The design verification report 199001-008: ZIIP 2.0 Verification Report states that it has raw data files and attachments, but these are not attached to the document and were not maintained by your firm. Additionally, the verification report references firmware testing without documenting the firmware build version.
b. Your IEC 60601-1 testing report prepared by an external laboratory does not have evidence of formal review or approval by ZIIP personnel as required by your SOP-14, Design Verification & Validation, version 1.0, eff. date 04/05/2022.
We reviewed your firm's responses and conclude that they are not adequate. Your response states that the interim verification activities were limited in scope, did not cover worst-case operating conditions, and did not incorporate the full sample size rationale required by the revised SOP, and expressly characterizes those activities as not a substitute for the comprehensive verification protocol. Comprehensive verification, including controlled protocols, worst-case testing, and controlled reports, was not completed by the original target dates; protocols are now committed by
(b)(4)
, and testing by
(b)(4)
. The response does not confirm that the firmware build version has been retrospectively documented in Verification Report 199001-008 or its protocol. Comprehensive verification testing for the
(b)(4)
safety-critical design inputs has not been completed. Your response does not confirm that the firmware version deficiency has been resolved within the original verification record.
2. Failure to adequately establish and maintain procedures for design validation, including adequate risk analysis as required by 21 CFR 820.30(g). Specifically,
a. Your firm failed to follow Risk Management Procedure, SOP-37, Rev. 3.0, eff. 5/26/2025 which describes your firm’s process for risk analysis and risk estimation. Your firm did not account for the information received from complaints as required by your procedure. Specifically:
i. Hazard ID ZIIP-HA-032, in the ZIIP 2.0 Hazard Analysis / Risk Management Plan and Report, Document Number: 199001-009, Rev. D, released 1/1/2026, classifies device overheating consequences as "brief, insignificant warming, damage to electronics; device shutdown" with "negligible" severity. SOP-37 Risk Management, v3.0, eff. 05/26/2025, establishes definitions for Severity of Harm to the Environment / Property, Probability of Harm, and Potential Harm to Consumer / Operator / User, including for "Negligible" severity: Inconvenience or minor discomfort to the user. However, your Complaint Log documented complaints from 2022 to 2025 that reported smoking, burning, or melting of devices, including:
Complaint 97490991 (3/7/2023): Customer "was burned by the zip and said it got very hot."
Complaint 97525276 (5/29/2023): Customer “notices a burning smell” and “noticed the Ziip was smoking.”
Complaint 97540550 (7/30/2023): states that “within 10 minutes it smelled like something was burning and it is the Ziip” and identifies a "serious malfunction which could pose fire/safety hazard and potentially cause serious injuries."
Complaint 97537231 (8/5/2023): States that “Ziip device melted the charging cord and charging port while charging and could have started a fire in my home had I not noticed the smell.”
Complaint 109765994 (6/27/2024): states “I plugged it in to charge and when I came back it had burned up.”
Complaint 114381725 (7/24/2024): states “I plugged in to charge this morning but after a while it appeared to be burning from the inside.”
Complaint 126746473 (10/9/2024): states “I realized it was in fact the device causing the burning smell” and “I am by no means comfortable sending off an electronic device that has shown flammable tendencies.”
Complaint 133307241 (11/18/2024): states “I plugging [sic] my Ziip halo in to charge, notices a burning plastic smell, and saw the charging cable melting/burning.”
Complaint 150108630 (2/15/2025): states “I plugged it in to charge and came back to find the device smoking and nearly melted at the charge point.”
Complaint 154680693 (3/16/2025): Device "almost burnt my fingers it was so hot" with metal casing changed shape.
These complaint descriptions appear to exceed conditions of “negligible” severity threshold defined in SOP-37. The complaints describe potential fire hazards and property damage, contradicting the "no discernible impact" definition.
ii. Hazard ID ZIIP-HA-003, in the ZIIP 2.0 Hazard Analysis / Risk Management Plan and Report, Document Number: 199001-009, Rev. D, released 1/1/2026, identifies the probability of fluid ingress into the charging port occurring as "remote" as defined by your procedure. SOP-37 Risk Management, v3.0, eff. 05/26/2025 establishes definitions for "Remote" probability: Hazard may occur but is very unlikely. However, CAPA 22 states that varying degrees of customer complaints related to gel intrusion into the charging port have been received, and since March 2024, your firm received
(b)(4)
verified complaints with gel, material, or moisture in the charging port.
The number of complaint descriptions including fluid ingress into the charging port appear to exceed conditions of a “remote” probability of occurrence.
We reviewed your firm's responses and conclude that they are not adequate. Revisions to
(b)(4)
and
(b)(4)
—the two hazard analyses cited in the FDA-483—have not been completed. The response states that internal drafts for
(b)(4)
and
(b)(4)
will be completed by
(b)(4)
, to be followed by clinical review. The retrospective and current-state trend analysis needed to support revised probability ratings for
(b)(4)
is dependent on the complaint retrospective review described under Observation 1, which remains incomplete. Your response does not describe any interim updates to labeling, instructions for use, or customer communications issued to address the identified risk characterization errors while the formal hazard analyses are being revised. Neither
(b)(4)
nor
(b)(4)
has been revised to reflect the post-market complaint data documented in the FDA-483. The severity and probability ratings identified as inaccurate remain in place in your firm's risk management documentation.
b. The ZIIP HALO User Guide, page 5, states that Golden Gels, Clear Gels, Silver Gels, and Crystal Gels can be used as alternatives to the Electric Complex Gel. Your firm’s SOP-14 Design Verification & Validation establishes that validation must ensure "device specifications conform to user needs and intended use(s)."
However, your firm did not provide adequate validation testing for the alternative conductive gels. Specifically:
i. The gel labeling lists multiple ingredients which would require biocompatibility testing; however, no biocompatibility testing was noted.
ii. Your Validation Plan and Protocol, rev. A, eff 3/31/2021, does not address testing for alternative gels.
iii. Your Validation Plan and Protocol, rev. A, eff 3/31/2021, section 6 states "
(b)(4)
will be subjected to the protocol.” Your ZIIP 2.0 Validation Report, Rev. A, 3/31/2021section 7 shows use of
(b)(4)
ZIIP HALO 2.0
(b)(4)
, with testing conducted by the General Manager. However, the use of
(b)(4)
does not appear to have been designed with documented statistical or scientific rationale.
We reviewed your firm's responses and conclude that they are not adequate. Comprehensive design validation under simulated use conditions for all marketed conductive gels has not been completed. Your response commits to completing validation protocols by
(b)(4)
, and testing and final reports by
(b)(4)
. The original target for executing comprehensive design validation was March 20, 2026. Training of
(b)(4)
and Regulatory Affairs personnel is in progress, with completion targeted by
(b)(4)
. Your response does not identify any interim restriction on the use or marketing of the four gels pending completion of validation and does not describe interim risk controls implemented in the absence of completed validation data. As of the May 15, 2026 response, gel compatibility validation testing has not been performed. The revised SOP and gel master list establish procedural requirements for future activities but do not constitute completion of the validation required to address the cited deficiency.
3. Failure to adequately establish and maintain procedures for corrective and preventive action, as required by 21 CFR 820.100(a). Specifically,
Your firm demonstrated premature CAPA closure and missing effectiveness checks. SOP-22, CAPA, Version 4.0, effective date 01/01/2026, the current CAPA procedure, and SOP-022 Version B, effective date 3/21/2019, the previous CAPA procedure, both establish requirements for CAPA documentation, investigation, implementation, and effectiveness verification. However, these procedures were not implemented.
a. SOP-022 Version B, effective date 3/21/2019, requires objective evidence of CAPA effectiveness on the CAPA Log Sheet. However, your firm’s CAPA Log Sheet listed that CAPAs 22, 33, 47, and 50, dated between October 2024 and July 2025, do not have documentation in the effectiveness check column.
b. CAPA 33, which updated complaint management procedures, was closed on December 31, 2025, the same date as the document change notice for the updated complaint management procedures. However, no evidence of verifications of the CAPA effectiveness verification was documented.
c. CAPA 50 was opened to address missed Safety Testing, IEC 60601-1, for a post-market design change, addition of a silicone charging port plug. The CAPA was opened on 7/14/2025 and was closed on 1/1/2026. The CAPA does not address why the necessary testing was not conducted, and there was no documented evidence of effectiveness verification.
We reviewed your firm's responses and conclude that they are not adequate. The retrospective review of the five cited CAPAs was not completed by the original February 6, 2026 target and is now committed for completion by
(b)(4)
. Your response cites resource constraints during concurrent remediation activities as the reason for the delay. Training of relevant personnel on the revised CAPA procedures, originally due February 13, 2026, was deferred and is committed for completion by
(b)(4)
. The effectiveness check, originally due February 20, 2026, is committed for completion by
(b)(4)
. Your
(b)(4)
response does not address the status of the five CAPAs individually cited in the FDA-483. The observation identified that five specific CAPAs were closed without completing required actions; the response does not confirm whether those CAPAs have been reopened. The retrospective review that would determine whether those CAPAs require reopening has not been completed.
4. Failure to adequately establish and maintain procedures for design change as required by 21 CFR 820.30(i). Specifically,
SOP-13, Design Controls, v. 2.0 and C, and SOP-14, Design Verification and Validation, v. 1.0, require design changes to be thoroughly reviewed for the need to repeat design verification and/or validation testing. However, your firm failed to properly document and evaluate design changes. For example:
a. App treatment protocol updates (October 2025) - New treatments were added without proper documentation or supporting verifications or validations.
i. Your App Revision History lists versions 2.0.1 through 3.6.2 with minimal detail, such as "bug fixes," and provides no evidence that functional changes were processed through design change control, and no evidence of evaluation for verification or validation.
ii. The HALO Treatment Summary documents treatment protocol changes made in October 2025 with eight (8) treatments having name/artwork/video changes but these were not documented through change control or evaluated for software verification/validation.
b. Firmware revisions - Your firm’s Firmware Revision History Log lists
(b)(4)
firmware builds (
(b)(4)
) from November 2014 through November 2024. However:
i. Eleven firmware revisions were made since May 2023, with inadequate documentation or supporting verifications or validations.
ii. Build 28 (1.0.27), dated 9/13/2023: "updated DAC Offset checks during programming" regarding correct electrical current output, does not have evidence of being processed through DCN process and no evidence of evaluation for verification or validation.
iii. Multiple builds entries state "bug fixes" with insufficient documentation to determine nature of changes, do not reflect determination of whether changes affect safety or performance, and contain no evidence of Design Change Notice (DCN) processing, nor do they include assessments for conducting supporting verifications or validations.
c.
(b)(4)
charging port plug (DCN 78) – The design change was implemented in November 2024, but not documented until January 1, 2026, and the documentation did not include supporting verification or validation, or a regulatory submission evaluation.
We reviewed your firm's responses and conclude that they are not adequate. DCN 78 has not been fully remediated; the response commits to updating DCN 78 to include the implementation date and to transition it to the revised DCN format by
(b)(4)
. Updates to the DHR and DMR to incorporate
(b)(4)
port plug specifications, drawings, bill of materials revisions, and supplier information are in progress, committed for completion by
(b)(4)
. Verification and validation of the
(b)(4)
charging port plug's effectiveness in preventing gel ingress—the device change implemented to address the overheating and melting complaints—has not been completed; protocol completion is targeted by
(b)(4)
, and testing by
(b)(4)
. Remediation of V&V gaps identified during the retrospective impact assessment for application and firmware changes is pending, committed for completion by
(b)(4)
.
DCN 78—the specific design change cited in the FDA-483 as having been implemented for approximately fourteen months without documentation, evaluation, or validation—has not been fully remediated as of the
(b)(4)
submission date. Verification and validation of the
(b)(4)
port plug remains incomplete. Remediation of V&V gaps for firmware and application changes also remains incomplete.
5. Failure to adequately establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR 820.198(a). Specifically,
Your firm failed to adequately establish procedures for receiving, reviewing, and evaluating complaints. 26 ZIIP HALO complaints lacked adequate investigation documentation or rationale for why no investigation was necessary, per SOP-028, Complaint Management.
SOP-028, effective 12/31/2025, requires investigation documentation on the "Troubleshooting Panel sheet" including order number, RMA number, complaint category, nature and details, investigation dates and results, engineering escalation status, and CAPA requirements in Section 7.4. However, the previous SOP-028 Version D, effective 3/3/2021 - 12/30/2025, required documentation of complaint investigations on Form F-028-01 to include: determination whether the device failed to meet specifications; whether the device was being used to provide treatment or diagnosis; and the relationship of the device to the reported incident or adverse event. The procedure states to document rationale if no investigation was performed in Section 7.6. For example,
a. Conversation 11783- Masseter muscle aching/twitching and lip immobility. Your firm categorized as "NONE" the device problem and "OTHER_INJURY" health effect. Your summary stated, "not escalated as there was no confirmed device malfunction." However, there was no documented investigation to confirm that the device was functioning properly.
b. Conversation 16861- Sharp electric shocks, dizziness, body feeling strange. Your firm categorized it as an "ELECTRICAL_ISSUE" and "PAIN." According to the complaint, the customer repeatedly requested a return but received troubleshooting questions from your firm. Your firm's summary states, "not escalated as there was no confirmed device malfunction." However, there was no documented investigation to confirm that the device was functioning properly, despite the customer's insistence the sensations were abnormal.
c. Ticket 97525276- Device smoking, buttons melted, device cracked. Your firm categorized it as "PHYSICAL_DAMAGE" with "NONE" as a health effect. A replacement was sent to the customer, but your firm did not document investigation of the cause of the device smoking, buttons melting, or why the device cracked.
d. Ticket 97537231- Device melted charging cord and port, could have started fire. Your firm categorized it as "POWER_ISSUE" with "NONE" as a health effect. Your firm initiated the replacement process but did not document an investigation.
Your firm provided templated responses as transcripts but did not document investigations or rationale for decisions to not investigate. Your firm did not follow SOP-028, which required the use of Form F-028-01 to document the investigation; assigned corrective actions; and record of the results of the investigation and/or corrective action.
We reviewed your firm's responses and conclude that they are not adequate. The retrospective review of the cited complaints and complaints from the preceding 24 months was not completed by the original February 27, 2026 target. Your response attributes this delay to the validation of an internal complaint triage system requiring additional time and commits to completing system verification and validation within two weeks of your May 15, 2026 response, with the retrospective review to be completed in the validated system by
(b)(4)
. The nine complaints requiring documented final reportability determinations remain unresolved as of the date of the
(b)(4)
submission. Your retrospective review of the 26 complaints cited in the FDA-483 has not been completed, and the nine complaint records identified as requiring documented final reportability determinations remain open. The response does not confirm that any of the specific complaint records cited in the FDA-483 have been remediated.
Unapproved/Misbranded Medical Device Violations
Through FDA’s review of the website https://ziipbeauty.com and of your user manual, we have determined that the ZIIP Halo 2.0, the ZIIP DOT, and the ZIIP Gels (Golden gel, Clear gel, Silver gel, Crystal gel, Electric complex gel) are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not for any of these devices have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g). These devices are also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not timely notify the agency of its intent to begin the introduction or delivery for introduction into interstate commerce for commercial distribution of the devices, as required by section 510(k) of the Act, 21 U.S.C. § 360(k).
You currently have a clearance, dated February 24, 2017, for the ZIIP Device, which is intended for facial stimulation, indicated for over-the-counter cosmetic use, and was cleared under K161484 as a Class II device under 21 CFR 882.5890. You also currently have a clearance, dated September 23, 2021, for the ZIIP+ Device, which is intended for facial and neck stimulation, is indicated for over-the-counter cosmetic use and was cleared under K212342 as a Class II device under 21 CFR 882.5890.
You do not have clearance, approval, or authorization for the ZIIP Halo 2.0. And the ZIIP Halo 2.0 is intended for uses different from those of the ZIIP Device and the ZIIP+ Device. Your firm’s promotion of the ZIIP Halo 2.0 provides evidence that the device is intended for:
i. Anti-aging
ii. Boost collagen
iii. Fade pigmentation
iv. Effective face pigmentation
v. Lymphatic drainage for the face
vi. Face Lift
vii. Plump lips
viii. Targeting sunspots
ix. Enhancement of blood circulation
x. Delivering oxygen and nutrients to the skin while helping to flush out toxins and excess melanin.
You also do not have a clearance, approval, or authorization for the ZIIP DOT. And the ZIIP DOT is intended for uses different from those of the ZIIP Device and those of the ZIIP+ Device. Your firm’s promotion of the ZIIP DOT provides evidence that the device is intended to:
i. reduce the appearance of spots,
ii. help clear and calm skin fast,
iii. reduce appearance of blemishes,
iv. rebalance skin microbiome and reduce redness by 87%.
The intended uses of the ZIIP Halo 2.0 and the ZIIP DOT go well beyond facial stimulation and neck stimulation, which are what the ZIIP Device and ZIIP+ Device are intended for. For example, the Halo 2.0 is intended for boosting collagen and the Halo DOT is intended for reduction of appearances of spots. The ZIIP Halo 2.0 and the ZIIP DOT are also not limited to cosmetic indications, as are the ZIIP Device and ZIIP+ Device. For example, the Halo 2.0 is intended to fade pigmentation and the Halo DOT is intended to help clear and calm skin fast.
In addition, you state that the ZIIP Halo 2.0 has been “re-engineered with advanced technology for stronger results and a more robust design for regular use.” (Emphasis in original.) A change or modification in a device that could significantly affect the safety or effectiveness of the device (for example, a significant change or modification in design, material, chemical composition, energy source, or manufacturing process) requires a premarket notification (21 CFR 807.81(a)(3)(i)).
Accordingly, you were required to submit to FDA a 510(k) for the ZIIP Halo 2.0 and the ZIIP DOT, either because they are new devices (21 CFR 807.81(a)(1), (2)) or, if the ZIIP Halo 2.0 or ZIIP DOT represents a change or modification from the ZIIP Device or the ZIIP+ Device, because they have been significantly changed or modified in design, components, method of manufacture, or intended use (21 CFR 807.81(a)(3)).
FDA has also reviewed the website information about the ZIIP Gels (Golden gel, Clear gel, Silver gel, Crystal gel, Electric complex gel). You state that these gels are registered as cosmetics. Yet your firm’s promotion of the gels provides evidence that the gels are intended, at least in part, to ensure “proper transmission of electrical currents to your skin during the Microcurrent facial treatment.” (FAQ sections “Do I Need to Use Conductive Gel? What Gels are Included?” Emphasis in original.) And conductive creams or gels used with external electrodes to reduce the impedance (resistance to alternating current) of the contact between the electrode surface and the skin are electroconductive media regulated by FDA as devices under 21 CFR 882.1275 (whether or not the ZIIP Gels might also constitute other products regulated by FDA). Indeed, your firm seems to have acknowledged as much, stating in the 510(k) summary for K161484 that the ZIIP Device “requires the use of a conductive gel” to “reduce the impedance between the electrodes and the skin of the user,” and noting that such gel is regulated under “§882.1275.”
You do not have clearance, approval, or authorization for the ZIIP Gels as devices. Based on our review of K161484, it appears that your firm sought clearance from FDA for conductive gel before withdrawing that component of its submission. Accordingly, you were required to submit to FDA a 510(k) for the ZIIP Gels, because they are new devices (21 CFR 807.81(a)(1), (2)).
For a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency. [21 CFR 807.81(b)(1)(i)] The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/HowtoMarketYourDevice/default.htm. The FDA will evaluate the information that your firm submits and respond as appropriate.
Our office requests that you immediately cease any activities that result in the misbranding or adulteration of your devices, such as the commercial distribution of your devices for the uses discussed above.
Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.
Other federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.
On February 2, 2024, the FDA issued a final rule amending the device current good manufacturing practice (CGMP) requirements of the Quality System (QS) Regulation under 21 CFR 820 to align more closely with the international consensus standard for Quality Management Systems for medical devices used by many other regulatory authorities around the world. The revised part 820, referred to as the Quality Management System Regulation (QMSR), became effective on February 2, 2026. Your most recent inspection on January 5, 2026, through January 12, 2026, was conducted pursuant to the QS Regulation, which was in effect at the time of the inspection. However, any corrective actions you propose, or implement must be pursuant to the QMSR requirements in effect as of February 2, 2026. For more information on the QMSR please refer to our frequently asked questions webpage: https://www.fda.gov/medical-devices/quality-system-qs-regulationmedical-device-current-good-manufacturing-practices-cgmp/quality-management-system-regulation-final-rule-amending-quality-system-regulation-frequently-asked.
Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and/or corrective actions (which should address systemic problems) that your firm has taken. If your firm’s planned corrections and/or corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and/or corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.
Your firm’s response should be sent via email to CDRHEnforcement@fda.hhs.gov. Please include in the subject line, CMS Case 725870 when replying. If you have any questions about the contents of this letter, please contact: Raymond Brullo at raymond.brullo@fda.hhs.gov
Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility or concerning your firm’s devices. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.
Sincerely,
/S/
Barbara C. Marsden
Director
Office of Regulatory Programs
Office of Product Evaluation and Quality
Center for Devices and Radiological Health For
Content current as of:
07/14/2026
Regulated Product(s)
Medical Devices